A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of NeoGenomics from a hold rating to a sell rating in a research note on Thursday, October 5th. BTIG Research lowered shares of NeoGenomics from a buy rating to a neutral rating in a research note on Monday, September 11th. BidaskClub lowered shares of NeoGenomics from a buy rating to a hold rating in a research note on Thursday, December 21st. Janney Montgomery Scott reaffirmed a buy rating on shares of NeoGenomics in a research note on Thursday, October 26th. Finally, CIBC set a $19.00 price target on shares of NeoGenomics and gave the stock a neutral rating in a research note on Wednesday. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $15.83.
Shares of NeoGenomics (NASDAQ:NEO) opened at $8.73 on Wednesday. The firm has a market cap of $689.91, a P/E ratio of -24.94, a PEG ratio of 3.46 and a beta of 0.84. NeoGenomics has a one year low of $7.12 and a one year high of $11.63. The company has a quick ratio of 1.99, a current ratio of 2.14 and a debt-to-equity ratio of 0.57.
A number of hedge funds have recently added to or reduced their stakes in NEO. Janus Henderson Group PLC acquired a new stake in NeoGenomics during the second quarter valued at approximately $20,651,000. Russell Investments Group Ltd. lifted its stake in NeoGenomics by 25.0% during the third quarter. Russell Investments Group Ltd. now owns 2,496,623 shares of the medical research company’s stock valued at $27,786,000 after purchasing an additional 499,913 shares during the last quarter. Columbus Circle Investors acquired a new stake in NeoGenomics during the third quarter valued at approximately $4,779,000. Segall Bryant & Hamill LLC lifted its stake in NeoGenomics by 318.0% during the third quarter. Segall Bryant & Hamill LLC now owns 374,068 shares of the medical research company’s stock valued at $4,163,000 after purchasing an additional 284,572 shares during the last quarter. Finally, Penn Capital Management Co. Inc. acquired a new stake in NeoGenomics during the second quarter valued at approximately $2,502,000. 83.43% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.com-unik.info/2018/01/06/scotiabank-analysts-give-neogenomics-neo-a-22-00-price-target.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
What are top analysts saying about NeoGenomics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics and related companies.